OBJECTIVE: To determine the validity of the World Health Organization Disability Assessment Schedule II (WHODAS II) in systemic sclerosis (SSc). METHODS: Patients enrolled in the Canadian Scleroderma Research Group registry participated in a standardized evaluation and completed the WHODAS II. Criterion validity was assessed by comparing the WHODAS II with the Medical Outcomes Study Short Form 36 (SF-36), construct validity was assessed by examining how it relates to common measures of outcome in SSc, and discriminative validity was assessed by examining how it distinguishes patients with more severe disease from those with less severe disease. RESULTS: A total of 402 patients with SSc were included (mean +/- SD age 55 +/- 13 years, 87% women, mean +/- SD disease duration 11 +/- 9 years). The mean +/- SD WHODAS II score was 24.6 +/- 17.4, and the greatest impairments were in life activities and mobility. There were moderate to good correlations between the WHODAS II and the SF-36 Physical Component Summary score (r = -0.44), the SF-36 Mental Component Summary score (r = -0.41), and measures of function (r = 0.54), depression (r = 0.44), pain (r = 0.40), and fatigue (r = -0.49, P < 0.0001 for all). The WHODAS II was able to consistently distinguish patients with milder disease from those with more severe disease. CONCLUSION: The WHODAS II had good psychometric properties in patients with SSc and should be considered a valid measure of health-related quality of life in SSc.
OBJECTIVE: To determine the validity of the World Health Organization Disability Assessment Schedule II (WHODAS II) in systemic sclerosis (SSc). METHODS:Patients enrolled in the Canadian Scleroderma Research Group registry participated in a standardized evaluation and completed the WHODAS II. Criterion validity was assessed by comparing the WHODAS II with the Medical Outcomes Study Short Form 36 (SF-36), construct validity was assessed by examining how it relates to common measures of outcome in SSc, and discriminative validity was assessed by examining how it distinguishes patients with more severe disease from those with less severe disease. RESULTS: A total of 402 patients with SSc were included (mean +/- SD age 55 +/- 13 years, 87% women, mean +/- SD disease duration 11 +/- 9 years). The mean +/- SD WHODAS II score was 24.6 +/- 17.4, and the greatest impairments were in life activities and mobility. There were moderate to good correlations between the WHODAS II and the SF-36 Physical Component Summary score (r = -0.44), the SF-36 Mental Component Summary score (r = -0.41), and measures of function (r = 0.54), depression (r = 0.44), pain (r = 0.40), and fatigue (r = -0.49, P < 0.0001 for all). The WHODAS II was able to consistently distinguish patients with milder disease from those with more severe disease. CONCLUSION: The WHODAS II had good psychometric properties in patients with SSc and should be considered a valid measure of health-related quality of life in SSc.
Authors: T Bedirhan Ustün; Somnath Chatterji; Nenad Kostanjsek; Jürgen Rehm; Cille Kennedy; Joanne Epping-Jordan; Shekhar Saxena; Michael von Korff; Charles Pull Journal: Bull World Health Organ Date: 2010-05-20 Impact factor: 9.408
Authors: Noelle E Carlozzi; Anna L Kratz; Nancy R Downing; Siera Goodnight; Jennifer A Miner; Nicholas Migliore; Jane S Paulsen Journal: Qual Life Res Date: 2015-01-31 Impact factor: 4.147
Authors: Monique Hinchcliff; Jennifer L Beaumont; Krishna Thavarajah; John Varga; Anh Chung; Sofia Podlusky; Mary Carns; Rowland W Chang; David Cella Journal: Arthritis Care Res (Hoboken) Date: 2011-11 Impact factor: 4.794
Authors: Lukia Namaganda Hamid; Olive Kobusingye; Sebastian Olikira Baine; Chrispus Mayora; Jacob A Bentley Journal: Ann Glob Health Date: 2017 May - Aug Impact factor: 2.462
Authors: Juan V Luciano; José L Ayuso-Mateos; Jaume Aguado; Ana Fernandez; Antoni Serrano-Blanco; Miquel Roca; Josep M Haro Journal: BMC Med Res Methodol Date: 2010-05-20 Impact factor: 4.615
Authors: Olatz Garin; Jose Luis Ayuso-Mateos; Josué Almansa; Marta Nieto; Somnath Chatterji; Gemma Vilagut; Jordi Alonso; Alarcos Cieza; Olga Svetskova; Helena Burger; Vittorio Racca; Carlo Francescutti; Eduard Vieta; Nenad Kostanjsek; Alberto Raggi; Matilde Leonardi; Montse Ferrer Journal: Health Qual Life Outcomes Date: 2010-05-19 Impact factor: 3.186
Authors: J Christopher Fowler; Michelle A Patriquin; Alok Madan; Jon G Allen; B Christopher Frueh; John M Oldham Journal: Int J Methods Psychiatr Res Date: 2016-09-27 Impact factor: 4.035
Authors: Renata M Sousa; Cleusa P Ferri; Daisy Acosta; Emiliano Albanese; Mariella Guerra; Yueqin Huang; K S Jacob; A T Jotheeswaran; Juan J Llibre Rodriguez; Guillermina Rodriguez Pichardo; Marina Calvo Rodriguez; Aquiles Salas; Ana Luisa Sosa; Joseph Williams; Tirso Zuniga; Martin Prince Journal: Lancet Date: 2009-11-28 Impact factor: 79.321
Authors: Renata M Sousa; Michael E Dewey; Daisy Acosta; A T Jotheeswaran; Erico Castro-Costa; Cleusa P Ferri; Mariella Guerra; Yueqin Huang; K S Jacob; Juana Guillermina Rodriguez Pichardo; Nayeli Garcia Ramírez; Juan Llibre Rodriguez; Marina Calvo Rodriguez; Aquiles Salas; Ana Luisa Sosa; Joseph Williams; Martin J Prince Journal: Int J Methods Psychiatr Res Date: 2010-03 Impact factor: 4.035